Somé AF et al., 2025-07: Phase 3 double-blind placebo-controlled cluster-randomized trial in Burkina Faso that found no reduction in childhood malaria incidence from repeated high-dose ivermectin MDA, although haemoglobin rose more in treated children and mosquito survival fell in the week after dosing.
The average estimated weekly malaria incidence rate per 100 person-weeks among children in the intervention group was 1·78 (95% CI 1·24-2·53) and 1·84 (1·29-2·64) in the control group, and the incidence rate ratio was 0·96 (95% CI 0·58-1·59; p=0·8723).
Somé AF et al., 2025-07: Phase 3 double-blind placebo-controlled cluster-randomized trial in Burkina Faso that found no reduction in childhood malaria incidence from repeated high-dose ivermectin MDA, although haemoglobin rose more in treated children and mosquito survival fell in the week after dosing. Phase 3, double-blind, placebo-controlled, cluster-randomized, parallel-group trial; 14 villages (7 per arm), Burkina Faso, two rainy seasons 2019-20; ~1928-2163 participants followed per year in the intervention arm and 1604-1921 in control; 703/686 and 605/641 children analysed. Dose: three daily oral doses of about 300 micrograms/kg by height band, monthly for up to eight rounds, integrated with seasonal malaria chemoprevention. Comparator: placebo MDA. MDA coverage 68-74%; all clusters received dual-chemistry Interceptor G2 nets mid-trial. Mosquito survival reduced the week after MDA in 2019 but not at 3 weeks; EIR ratio 0.91 (0.56-1.30). Funded by NIAID (U01 AI138910). Declared interests: BDF and SP served on a scientific advisory board for MedinCell on a long-acting ivermectin formulation; all other authors none. Bearing CONTRADICTS the claim that ivermectin MDA reduces malaria: the primary endpoint was null, with the authors naming low incidence, net distribution and overdispersion as possible explanations. Study type: randomized trial.
